SCHEMBL5454317

SCHEMBL5454317

NC(=O)c1c(NC(=O)Nc2ccc(Cl)c(Cl)c2)sc2c1CCOC2

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.63
KMT2A Q03164 2/20 0.63
KDM4E B2RXH2 1/20 0.63
USP2 O75604 1/20 0.63
LMNA P02545 1/20 0.63
MAPT P10636 1/20 0.63
HTT P42858 1/20 0.63
ATM Q13315 1/20 0.63
CFTR P13569 1/20 0.56
KCNH2 Q12809 9/20 0.56
CNR2 P34972 3/20 0.48
CNR1 P21554 2/20 0.48
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
EPHB4 P54760 1/20 0.47
ANO1 Q5XXA6 2/20 0.46
CXCR2 P25025 1/20 0.46
EPHX1 P07099 1/20 0.46
EPHX2 P34913 1/20 0.46
PTPRC P08575 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5453060 0.92 CFTR (0.54) MEN1KMT2AKDM4EUSP2LMNA
SCHEMBL16962264 0.89 KCNH2 (0.68) MEN1KMT2AKDM4EUSP2LMNA
SCHEMBL5460167 0.88 KDR (0.60) MEN1KMT2AKDM4EUSP2LMNA
SCHEMBL5467205 0.88 CFTR (0.56) MEN1KMT2AKDM4EUSP2LMNA
SCHEMBL5457877 0.87 CFTR (0.57) MEN1KMT2AKDM4EUSP2LMNA
SCHEMBL5450806 0.86 CFTR (0.57) MEN1KMT2AKDM4EUSP2LMNA
SCHEMBL5451228 0.85 CFTR (0.61) MEN1KMT2AKDM4EUSP2LMNA
SCHEMBL5465615 0.85 KCNH2 (0.53) MEN1KMT2AKDM4EUSP2LMNA
SCHEMBL5460074 0.85 MEN1 (0.67) MEN1KMT2AKDM4EUSP2LMNA
SCHEMBL5446242 0.84 CFTR (0.55) MEN1KMT2AKDM4EUSP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 MEN1 2891/4885KMT2A 4785/4885KDM4E 3417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.